The 17th World ADC San Diego agenda tells you exactly where antibody-drug conjugate development is heading in 2026: new payload mechanisms, new formats, earlier lines of therapy, and real pressure on manufacturing cost. Here is what attendees are talking about this week, what each shift means for CMC, and how the DES Pharma team at Booth 44 can help.
TL;DR
- World ADC San Diego 2026 brings together 1,300+ attendees from 400+ companies across seven content tracks, from early chemistry through manufacturing and supply.
- Three themes dominate the agenda: payload mechanisms beyond topoisomerase I, new formats such as bispecific and dual-payload ADCs, and moving ADCs into earlier lines of oncology treatment.
- Each of those shifts lands on CMC: harder characterization, tighter containment, more complex supply networks, and dose justification that FDA will examine closely.
- DES Pharma principals covering process development, analytics, supply chain, quality, and safety are at Booth 44 through October 15. Book a meeting or stop by.
Why the 2026 Agenda Matters to CMC Teams
The organizers built this year's program around three goals: de-risking differentiated payload mechanisms beyond topoisomerase I (Topo1), widening ADC impact in the clinic, and adapting manufacturing so novel ADCs can be made efficiently and at a reasonable cost. Two of those three goals are CMC problems as much as scientific ones.
The commercial stakes explain the urgency. Grand View Research values the global ADC market at USD 14.5 billion in 2025 and projects USD 32.1 billion by 2033, with North America holding 39.8% of 2025 revenue. Cleavable linkers account for 67.7% of revenue, and topoisomerase I inhibitor payloads are the fastest growing payload segment.
The same report names the main restraint just as clearly: ADC production combines biologics manufacturing with highly potent cytotoxic compounds, so small variations in the conjugation process can affect consistency, efficacy, and safety. That is the gap between a promising molecule and a filing-ready program, and it is where DES Pharma works.
Global ADC Market: Published Values and 2033 Forecast (USD Billions)
Who Is in the Room at World ADC 2026
World ADC is the longest-running ADC congress, and the 2026 edition is its largest yet by the organizer's figures: 1,300+ attendees, 400+ companies, 170+ speakers, and a seniority mix where 65% of attendees are Director level or above. Large sponsors are sending full teams rather than a single scientist, which signals portfolio-level investment in conjugates.
At the other end of the spectrum, 14 companies are presenting at World ADC for the first time, including Aarvik Therapeutics, Avenzo Therapeutics, Callio Therapeutics, Immunome, MediLink Therapeutics, and NEOK Bio. Emerging sponsors like these tend to have strong science and thin CMC benches, so the questions they bring to the exhibit hall are practical: which CDMO can actually handle our payload, how do we set a DAR specification we can defend, and what will FDA ask at the pre-IND meeting.
Largest Company Delegations Listed for World ADC San Diego 2026
Seven Conversations Driving World ADC San Diego 2026
The program runs across seven tracks: early chemistry, target biology, preclinical, translational medicine, clinical lessons, process and analytical development, and manufacturing and supply. Read across them and seven conversations stand out. Each one maps to a specific DES Pharma capability.
1. Payloads Beyond Topoisomerase I
The 2026 agenda features novel cytotoxic mechanisms including pan-PI3K/mTOR inhibitors, protein alkylation, antifolate ADCs, and translation inhibitors, along with first-time data from AstraZeneca on PROTAC ADCs. After several years of topoisomerase I payload dominance, the field is looking for differentiation.
Every new payload class resets the CMC playbook. Hydrophobicity changes conjugation behavior and aggregation risk, potency drives the occupational exposure band and cleaning limits, and free-payload methods must reach new sensitivity targets. DES Pharma's ADC process development team works through linker-payload compatibility, reaction condition screening, and containment readiness for OEB 4 and 5 compounds before a new payload reaches a GMP suite.
2. New Formats: Bispecific, Dual-Payload, and Novel Conjugates
Bispecific ADCs (bsADCs), dual-payload ADCs (dpADCs), degrader-antibody conjugates (DACs), immune-stimulating antibody conjugates (ISACs), antibody-oligonucleotide conjugates (AOCs), and conditionally active ADCs all appear on this year's program. These formats promise better selectivity or resistance coverage, but they multiply the analytical burden.
A dual-payload molecule has two drug-load distributions to characterize; an AOC brings oligonucleotide-related impurities into a biologics release panel. One assay rarely tells the full story. DES Pharma builds ADC analytical and QC strategies that combine HIC-HPLC, RP-HPLC, LC-MS, peptide mapping, and mechanism-based potency assays, so each critical quality attribute is covered by orthogonal methods that will transfer into QC. For first-in-human planning on these formats, our team's guide on de-risking your first ADC submission is a useful starting point.
3. Earlier Lines of Therapy and the Dose Question
Organizers highlight readouts and approvals moving ADCs into first-line metastatic settings and into neoadjuvant and adjuvant use. The clinical track includes a University of Chicago session on I-SPY2 data and toxicity monitoring for early-stage triple-negative and HER2-positive breast cancer.
Earlier-line patients are healthier and stay on therapy longer, so tolerance for cumulative toxicity is lower and dose justification matters more. FDA's clinical pharmacology guidance for ADCs sets expectations for bioanalytical methods, dosing strategy, exposure-response analysis, immunogenicity, and drug-drug interactions. We covered the practical side in why the MTD is not a dose justification. DES Pharma's ADC medical safety and pharmacovigilance support adds signal detection, dose modification guidance, and aggregate safety review as programs expand.
4. Closing the Translational Gap
The preclinical track centers on upgrading the toolbox to reduce mismatch between animal data and clinical outcomes, while the translational track focuses on patient selection, dosing, and trial design. Sutro Biopharma is presenting early clinical safety and PK data on STRO-004 and how its design choices connect to clinical performance.
For CMC teams, the translational question is whether the material that generated the tox data is representative of the clinical process. DES Pharma helps sponsors set phase-appropriate specifications under ICH Q6B, plan comparability before process changes, and build IND-enabling CMC packages that hold up. Our ADC consulting overview lays out how those pieces connect from preclinical through commercial readiness.
5. Process Control and Characterization at Scale
The process and analytical development track aims to produce complex conjugates quickly and with confidence. Merck is presenting computational and mechanistic work on chemoselective reduction for engineered cysteine site-specific ADCs, and MacroGenics is sharing data on containment bags as a development tool in ADC lyophilization.
These sessions point to the same priorities DES Pharma works on daily: DAR control that holds across scale, purification trains that clear free payload and unconjugated antibody, qualified scale-down models, and process characterization that supports PPQ. That is the core of our program and process development practice, and the reason we framed our San Diego plans around engineering confidence in ADC development.
6. Cost-Effective Manufacturing and Outsourced Supply
The manufacturing and supply track is built around streamlining internal and outsourced CMC strategy so ADCs can be manufactured cost-effectively at scale. The partner roster reflects how outsourced this field is: the lead and senior partners include WuXi XDC, Ajinomoto Bio-Pharma Services, Abzena, Cytiva, and Veranova.
Walking the exhibit hall is a fast way to meet CDMOs; choosing one is harder. DES Pharma's ADC supply chain and potent compound procurement team designs RFPs that test real ADC fit, assesses contained conjugation capacity, and builds dual-sourcing plans for linker-payload intermediates. For more depth, read how outsourcing decisions predict clinical supply stockouts, how to protect ADC stability through clinical site handling, and our joint tech transfer and cold chain briefing with Adept Packaging.
7. Quality Systems That Hold Up Under Inspection
Quality does not get its own track at World ADC, but it runs underneath every one of them. ADC QA has to cover biologic GMP and potent compound control at the same time: cleaning validation with cytotoxic carryover risk, batch release that combines DAR, potency, and residual free payload data, and change control for antibody source and linker-payload lots.
DES Pharma's ADC quality assurance consultants build those systems before an inspection forces the issue. When an inspection has already gone badly, our guides on responding to an FDA Form 483 and consent decree remediation lay out the recovery path.
Agenda Theme to DES Service: Quick Map
Use this table to decide which DES Pharma principal to ask for at Booth 44.
| World ADC 2026 theme | What attendees are asking | DES Pharma service |
|---|---|---|
| Payloads beyond Topo1 | How do we scale a new payload class safely and keep DAR consistent? | ADC Process Development |
| bsADCs, dpADCs, DACs, AOCs | How do we characterize two payloads or a non-traditional payload? | ADC Analytical Development and QC |
| Earlier-line oncology | How do we justify dose and manage safety signals as populations grow? | ADC Medical Safety and Pharmacovigilance |
| Translational gap | Is our tox material representative of the clinical process? | ADC CMC Strategy |
| Process control at scale | Will our conjugation and purification hold at clinical and commercial scale? | Program and Process Development |
| Cost-effective outsourced supply | Which CDMO actually fits our payload, and where are the supply risks? | ADC Supply Chain and Procurement |
| Inspection readiness | Is our QMS built for potent compounds and conjugated biologics? | ADC Quality Assurance |
Who You Will Meet at Booth 44
The DES Pharma team in San Diego is made up of principals who have run the work themselves, not account managers. Meeting requests are routed to the principal whose experience fits your modality, function, and program stage.
Bioprocess design, scale-up, IND-enabling CMC strategy, technology transfer, and cost-of-goods optimization.
CDMO evaluation, contracting and oversight, commercial launch and global tech transfer, supply network optimization.
Quality by Design, DoE modeling, process characterization, scale-down model qualification, and PPQ readiness.
Pharma enterprise software, AI-powered applications, and large-scale systems integration for development teams.
"ADC development is inherently cross-functional. Success depends not only on the science, but also on how effectively process development, analytics, quality, manufacturing, and supply chain work together."
Meade Medaugh, DES Pharma, in the World ADC San Diego 2026 announcement
Meet DES Pharma at Booth 44
Bring your toughest ADC question: a DAR specification you are not sure you can defend, a CDMO shortlist, a payload supply risk, or a dose justification due before Phase 2. We will tell you plainly what we would do.
Not in San Diego This Week?
If you are following World ADC from your desk, the conversations above do not end on October 15. Our recent ADC series covers the same ground in more depth, and the team is available for calls after the event through the DES Pharma contact page.
- From Drug Substance to Shelf-Ready: A DES x Adept Briefing on Tech Transfer and Cold Chain Packaging
- Cold Chain and Bedside Stability: Ensuring Your ADC Survives Global Clinical Site Handling
- Outsourcing ADC Manufacturing: Predict Clinical Supply Stockouts
- From Preclinical Lead to Clinic: De-Risking Your First-in-Human ADC Submission
- The MTD Is Not a Dose Justification: What FDA Now Expects at the ADC Phase 2 Transition
- DES Pharma to Attend 17th World ADC San Diego 2026
- Engineering Confidence in ADC Development: Let's Connect in San Diego
- How to Structure a Multi-Year Remediation Program After a Consent Decree
- How to Respond to an FDA Form 483: A Step-by-Step Guide
Booth 44 Briefing: Your World ADC Questions, Answered
When and where is World ADC San Diego 2026?
The 17th World ADC San Diego runs October 12 to 15, 2026, at the Town and Country Resort, 500 Hotel Circle North, San Diego, California. It is organized by Hanson Wade and is the longest-standing global conference dedicated to antibody-drug conjugates.
Where can I find DES Pharma at the conference?
DES Pharma is exhibiting at Booth 44 throughout the event. You can book a specific time through the DES World ADC Calendly page, submit the meeting request form, or connect with the team through the World ADC event app.
What ADC services does DES Pharma offer?
DES Pharma supports ADC programs across five service areas: process development and conjugation CMC, analytical development and QC, supply chain and potent compound procurement, quality assurance and potent compound GMP, and medical safety and pharmacovigilance. Support runs from preclinical planning and IND-enabling work through PPQ, commercial launch, and post-approval changes.
Does DES Pharma work on bispecific, dual-payload, or other novel conjugates?
Yes. The DES meeting request form for World ADC lists bispecific and dual-payload ADCs and novel conjugates such as DACs, AOCs, and ISACs as discussion areas, alongside conventional ADCs. DES process work covers auristatin, maytansinoid, and topoisomerase I payload systems, cleavable and non-cleavable linkers, and site-specific conjugation platforms.
Can DES Pharma help us choose an ADC CDMO?
Yes. DES evaluates CDMOs against real ADC requirements: contained conjugation capacity, potent compound handling, analytical capability for DAR and free payload, campaign scheduling, and the pathway to commercial scale. The team also drafts RFPs, quality agreements, and tech transfer readiness assessments.
What should I bring to a Booth 44 meeting?
The most productive meetings start with your program stage, payload class and linker type, target DAR range, current CDMO or manufacturing status, and the next regulatory milestone. Even a one-page summary lets the right principal give you specific feedback instead of general advice.
I cannot attend World ADC. How do I reach the DES team?
Use the DES Pharma contact page or email contactus@despharmaconsulting.com. The same principals who are in San Diego are available for follow-up calls after the event.
Sources
- Hanson Wade. 17th World ADC San Diego, October 12 to 15, 2026: program themes, tracks, attendance, and teams attending. https://worldadc-usa.com/
- Grand View Research. Antibody Drug Conjugates Market Size Report, 2026 to 2033. https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market
- U.S. Food and Drug Administration. Clinical Pharmacology Considerations for Antibody-Drug Conjugates: Guidance for Industry (March 2024). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry
- DES Pharma. DES Pharma to Attend 17th World ADC San Diego 2026. https://despharmaconsulting.com/des-pharma-to-attend-17th-world-adc-san-diego-2026/
About DES Pharma
DES Pharma (Dynamic Engineering Solutions) is a global partner in drug development, providing integrated CMC, analytical, quality, and supply chain solutions to biotechnology and pharmaceutical companies. With a focus on speed, precision, and compliance, DES Pharma helps clients advance life-changing therapies efficiently and confidently. Learn more at despharmaconsulting.com.
Media contact: Diana Lee, Diana@AsianInNY.com



